Nanite develops programmable, tissue-specific polymer nanoparticles (PNPs) and an AI-driven design platform, SAYERTM, to enable non-viral gene delivery. Its core product approach combines AI-driven polymer design with multiplexed in vivo screening to produce fit-for-purpose delivery vehicles. The company aims to deliver DNA-encoded therapeutics that durably express neutralizing antibodies in vivo, targeting indications such as HIV. Nanite positions its technology to overcome limitations of viral vectors and lipid nanoparticles by prioritizing tissue specificity and safety. The company says it seeks to expand access to gene therapy for underserved populations. Nanite is headquartered in Boston, MA and recently received a $1.8M grant to support this work. Nanite develops programmable polymer nanoparticles (PNPs) and an AI-driven discovery platform called SAYER™ to design fit-for-purpose non-viral delivery vehicles for genetic cargo. SAYER couples high-throughput automated polymer synthesis and in vivo screening with artificial intelligence to rapidly explore chemical space and identify PNP candidates. The company positions PNPs as potentially less immunogenic and more stable and versatile than viral vectors or some lipid nanoparticles. With new funding from the Cystic Fibrosis Foundation, Nanite will initially focus on delivering messenger RNA therapies to the lung and on particles that can better resist the thick mucus in CF patients. Nanite plans to expand the technology to deliver other types of gene therapies and to target additional organs affected by cystic fibrosis, such as the pancreas. The company is headquartered in Boston, MA and recently announced a $6M seed financing in addition to the up-to-$2M CF Foundation investment.

Total raised

$4M

Funding rounds

2

Latest round

Grant

Latest activity

May 2024